Proshares Pet Care ETF

US Bank Upgrades Nestle Rating to Buy

Chewy Inc. CTO Satish Mehta Disposes of Common Stock

Merck Raises $8 Billion Through Multiple Tranches of Notes

FDA Approves Merck's New Parasitic Drug for Cattle

FDA Senior Official Richard Pazdur's Retirement Sparks Industry Attention

Panagora Asset Management Inc. reduces holdings in Merck & Co., Inc. stock

TD Cowen Analyst Reiterates Buy Rating on Chewy with a $47.00 Price Target

Merck's stock rises 1.3% after Goldman Sachs upgrades target price

TD Cowen Analyst Reiterates Buy Rating on Zoetis

River Wealth Advisors LLC Increased Holdings in Merck

Granite Investment Partners LLC Reduced Holdings in IDEXX Laboratories

Chewy to Report Q3 2026 Earnings

Chewy to release FY2026 Q3 earnings on December 10, 2025, pre-market EST; forecast revenue USD 3.095 B, EPS USD 0.1232

Isthmus Partners Invests $1.03 Million in Merck & Co. in Q2

Sio Capital Reduces Stake in Merck

Zoetis Announces Latest R&D Progress, Expanding into New Therapeutic Areas

Nestle India Receives 82.8 Million Rupees in Tax Fines

Nestle and JPMorgan Evaluate Blue Bottle Coffee's Future, Potential Sale Considered

UK and US Reach Zero Tariffs on Pharmaceutical Exports

Merck Seeks to Raise Up to $8 Billion in US Bond Sale Linked to Cidara Transaction

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

HALO

Health-care stocks fell sharply as traders shifted to rate-sensitive sectors. Halozyme secured a preliminary injunction against Merck & Co. in a patent dispute over Keytruda in Germany. The Trump administration's biomedical innovation goals face challenges within the FDA, amid infighting and staff turnover influenced by Robert F. Kennedy Jr.'s policy changes.

marketscreener

Merck

Halozyme Therap

Health Care Down Sharply on Rotation to Rate-Sensitive Sectors -- Health Care Roundup

CHWY

05:14 PM EST, 12/04/2025 (MT Newswires) -- Satish Mehta, Chief Technology Officer, on December 02, 2025, sold 14,928 shares in Chewy (CHWY) for $501,774. Following the Form 4 filing with the SEC, Mehta has control over a total of 617,302 Class A common shares of the company, with 617,302 shares held directly.SEC Filing: MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

fidelity

Chewy

Chewy Insider Sold Shares Worth $501,774, According to a Recent SEC Filing

Officer Mehta of Chewy Inc filed a Form 4 with the SEC, disclosing a planned surrender of 6,056 shares and a planned sale of 8,872 shares, totaling $297,478, executed under a 10b5-1 trading plan. Ending holdings are 617,302 shares directly.

Reuters

Officer Mehta Sells 8,872 ($297.5K) Of Chewy Inc [CHWY]

CEO Singh Sumit of Chewy Inc surrendered 41,428 shares back to the company at $33.73 per share, totaling $1,397,549, to cover option exercise costs and tax liabilities. This was executed under a prearranged trading plan (10b5-1). Singh's ending holdings are 2,841,864 shares, with 2,542,225 direct and 299,639 indirect.

CEO Singh Surrenders 41,428 Of Chewy Inc [CHWY]

Satish Mehta, CTO of Chewy Inc., has reported the disposal of common shares of the company. The filing is available via EDGAR, the SEC's system. This news is generated by AI and is not financial advice.

Chewy Inc. CTO Satish Mehta Reports Disposal of Common Shares

Zoetis Inc. (ZTS) shares fell 1.76% to $120.41 on Thursday, marking the fourth consecutive day of losses. The stock underperformed compared to competitors like Merck & Co. Inc. and IDEXX Laboratories Inc. Trading volume was higher than the 50-day average. Zoetis is 33.79% below its 52-week high of $181.85. The S&P 500 rose 0.11%, while the Dow Jones fell 0.07%.

Dow Jones

Zoetis

Zoetis Inc. Stock Underperforms Thursday When Compared To Competitors

Merck & Co., Inc. has raised $8 billion through a multi-tranche notes offering, including various debt instruments with maturities ranging from 2029 to 2065. The offering closed on December 4, 2025, under the company's shelf registration statement filed with the SEC. This capital raising effort involves several series of notes with varying interest rates and maturities.

Merck Raises $8 Billion in Multi-Tranche Notes Offering

Scotiabank raised its target price for Merck & Co., Inc. (NYSE:MRK) from $105.00 to $120.00, giving the stock a "sector outperform" rating. This suggests a potential upside of 18.98% from the current price. Other analysts have mixed ratings, with some upgrading and others downgrading their ratings. Merck's recent earnings report showed a revenue increase of 3.7% year-over-year and an EPS of $2.58, beating estimates. The company has set its FY 2025 guidance at 8.930-8.980 EPS.

Market Beat

Scotiabank Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

Merck says Exzolt Cattle-CA1 to be available by prescription in Q1 2026

Merck says Exzolt Cattle-CA1 to be available by prescription in Q1 2026

The FDA has conditionally approved Merck's EXZOLT CATTLE-CA1, a novel parasiticide for preventing and treating New World screwworm larvae and controlling cattle fever tick in cattle. This marks the first introduction of a new ectoparasiticide for beef cattle in decades. The product has also received market authorization in Mexico. The approval was achieved through an accelerated regulatory pathway.

FDA Conditionally Approves Merck's EXZOLT CATTLE-CA1 for Screwworm Prevention in Cattle

Panagora Asset Management Inc. sold 770,925 shares of Merck & Co., Inc., reducing its position by 94.1% in Q2. Merck's stock opened at $102.37, with a 1-year high of $105.84. The company reported Q3 earnings of $2.58 per share, beating estimates. Merck increased its quarterly dividend to $0.85 per share, yielding 3.3%. EVP David Michael Williams sold 8,614 shares, decreasing his position by 25.95%.

Panagora Asset Management Inc. Sells 770,925 Shares of Merck & Co., Inc. $MRK

RFK Jr.'s vaccine panel will vote on changing the hepatitis B shot recommendation for newborns, potentially impacting public health. The current recommendation has reduced infections by 99% since 1991. Experts warn that changes could increase chronic infections among children. The panel's decision, influenced by newly appointed members, could affect insurance coverage and public health outcomes. Despite concerns, studies show the vaccine is safe and effective. Merck opposes changes, citing risks to children's health.

CNBC

RFK Jr.'s vaccine panel to vote on changing hepatitis B shot recommendation for babies

IDXX

How Is IDEXX Laboratories’ Stock Performance Compared to Other Health Care Stocks?

Barchart Option

IDEXX Labs

How Is IDEXX Laboratories’ Stock Performance Compared to Other Health Care Stocks?